Breeding hope as rare fossa arrives at zoo from US
A rare male fossa has arrived at Chester Zoo from America as part of an international breeding programme to protect the species from extinction.
The seven-year-old fossa, named Zaza, has travelled from an enclosure in San Diego after being genetically matched with the zoo's female fossa, Shala.
Native to Madagascar, the long-tailed, cat-like mammal is a highly threatened species with fewer than 2,500 estimated to remain in the wild.
Chester Zoo's head of mammals Mark Brayshaw said the move was "an important part of the international effort to ensure this wonderful and unique species is safeguarded long into the future".
Conservationists in Chester have worked alongside international partners in Madagascar to protect habitats on the island for over 15 years.
Female Shala, who arrived in Chester in 2018, previously had a litter of pups with former mate Isalo and has also been part of a project to monitor mating calls.
Her mating call was recorded and analysed to help researchers in the rainforests of Madagascar to identify when female fossas are looking for mates in the wild and identify the best environments for breeding.
Females only come into season once a year for a two-week period when the usually-silent species become very vocal.
Keeper Jack Cunningham, a member of the Carnivore team at Chester Zoo, said the pair will be introduced slowly.
Lucy Pearson, a keeper at San Diego Zoo, said Zaza was a "very energetic and well-tempered" fossa and "the bravest of the four pups in his litter due to his curious personality".
Fellow keeper Candice Dymek said while it was "hard to say goodbye" to Zaza the zoo was "excited at the potential for him to sire pups and grow the European fossa population, and to be a part of such a large collaboration that will continue to further conservation efforts in Madagascar".
Read more stories from Cheshire on the BBC, watch BBC North West Tonight on BBC iPlayer and follow BBC North West on X. You can also send story ideas via Whatsapp to 0808 100 2230.
Sloth has pioneering surgery to cure toothache
Zoo's new science centre to help endangered species
'Giant spiders' thriving in wild after zoo release
Capturing birth of smallest wild cattle 'special'
Zoo plants 19,000 trees in unused field
Chester Zoo
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Small Ear-Wax Sample, Big Diagnostic Clues
A recent BBC report suggests that cerumen, commonly known as earwax, may harbor biomarkers to aid in the diagnosis and monitoring of conditions such as cancer, Alzheimer's disease, and metabolic disorders. Cerumen Profile The primary function of cerumen is to keep the external auditory canal clean and lubricated, preventing invasion by bacteria, fungi, and insects. Beyond this, cerumen may reflect systemic metabolism by concentrating a broader array of compounds than blood, urine, sweat, and tears. Its relative stability allows the accumulated cerumen to provide long-term snapshots of metabolic changes. Disease Associations Researchers have defined genetically determined wet and dry cerumen phenotypes. In the US, Caucasian, African American, and German women with wet cerumen faced roughly four times the risk of dying from breast cancer compared with Japanese and Taiwanese women with dry cerumen. The study found that Japanese women with breast cancer were more likely to carry the wet-cerumen allele than were healthy controls. However, large-scale studies in Germany, Australia, and Italy failed to confirm these associations. A recent analysis reported that patients with Ménière's disease had lower levels of three fatty acids in the cerumen compared with healthy controls — the first biomarker identified for that disorder. In a 2019 study led by Nelson Roberto Antoniosi Filho, PhD (Federal University of Goiás Goiânia in Brazil), researchers analyzed cerumen samples from 52 patients with lymphoma, carcinoma, or leukemia and 50 healthy volunteers, using a method that identifies volatile organic compounds (VOCs). The researchers identified 27 VOCs that served as diagnostic fingerprints for cancer, predicting the cancer status with 100% accuracy. The assay could not distinguish among cancer types, indicating that these VOCs represent a general response to malignant cells. Another investigation by the same group showed that cerumen analysis can detect metabolic disturbances in premalignant stages when cells exhibit dysplastic changes that may lead to cancer but remain nonmalignant, potentially enabling much earlier intervention. The team is also investigating whether metabolic alterations caused by neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, can be detected in the cerumen. Diagnostic Tool Antoniosi Filho and colleagues proposed that cancer, as a mitochondrial metabolic disorder, releases VOCs that accumulate in cerumen, allowing differentiation between healthy and cancerous individuals via an assay they call the cerumenogram. The aim was to develop a cerumenogram as a diagnostic tool to accurately predict certain cancers from a small cerumen sample. Clinical Adoption Hospital Amaral Carvalho in Jaú, São Paulo — a national reference center for oncology and bone marrow transplantation — has recently implemented cerumenograms for cancer diagnosis and monitoring. Future Directions An April 2025 paper in Scientific Reports by Antoniosi Filho concluded that the cerumenogram could: 1. Identify oncologic risk by detecting premalignant cells before cancer onset, introducing a novel screening modality 2. Show that mitochondrial impairment in premalignant cells — such as hypermetabolic inflammation and dysplasia — produces the same VOC biomarkers as malignant cells, distinct from those in benign lesions, opening new paths for risk management and early intervention 3. Correlate cerumenogram findings with established imaging techniques such as 2-deoxy-2-[fluorine-18] fluoro-D-glucose PET/CT (18F-FDG PET/CT) and gallium-68 PSMA PET/CT, demonstrating alignment with clinical results while offering a noninvasive, lower-cost alternative 4. Monitor treatment response and cancer remission, supporting assessment of therapeutic efficacy and cellular return to normal 5. Confirm metabolic indicators of malignancy to guide clinical decisions alongside imaging and biopsy 6. Drive the development of targeted therapies aimed at metabolites overproduced in malignant conditions. In conclusion, the cerumenogram may serve as a valuable assay for evaluating precancerous indicators, cancer progression, and remission, with the potential to reduce mortality, alleviate patient suffering, and lower disease-related costs. Congratulations to Nelson Roberto Antoniosi Filho, PhD, and his team.
Yahoo
3 hours ago
- Yahoo
Japanese lunar lander crashes while attempting touchdown on the Moon
A private lunar lander from Japan crashed while attempting a touchdown on Friday, the latest casualty in the commercial rush to the Moon. Tokyo-based company ispace declared the mission a failure several hours after communication was lost with the lander. Flight controllers scrambled to gain contact, but were met with only silence and said they were concluding the mission. Communications ceased less than two minutes before the spacecraft's scheduled landing on the Moon with a mini rover. Until then, the descent from lunar orbit seemed to be going well. Takeshi Hakamada, ispace chief executive officer and founder, apologised to everyone who contributed to the mission, the second lunar strikeout for the company. Two years ago, the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience carried a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house for placement on the Moon's dusty surface. Company officials said it was too soon to know whether the same problem doomed both missions. 'This is the second time that we were not able to land. So we really have to take it very seriously,' Mr Hakamada told reporters. He stressed the company would press ahead with more lunar missions. A preliminary analysis indicates the laser system for measuring the altitude did not work as planned and the lander descended too fast, officials said. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' the company said in a written statement. Long the province of governments, the Moon became a target of private outfits in 2019, with more flops than successes along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the Moon faster and became the first private entity to successfully land there in March. Another US company, Intuitive Machines, arrived at the Moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the south pole and was declared dead within hours. Resilience was targeting the top of the Moon, a less treacherous place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Plans had called for the 7.5ft Resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fibre-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for Nasa. The rover was going to stick close to the lander, going in circles at a speed of less than one inch per second.
Yahoo
3 hours ago
- Yahoo
Finland's AIATELLA secures funds for AI cardiovascular imaging solutions
Finnish startup AIATELLA has raised €2m ($2.27m) in financing to develop and scale its cardiovascular imaging technology powered by AI. The investment will support the company in conducting clinical trials and further developing its ultrasound-based preventative screening tool, which can identify and quantify carotid artery narrowing within minutes. Nordic Science Investments spearheaded the funding round, with contributions from Specialist VC, Business Finland, and Harjavalta Ventures, among other investors. The Automated Image Measurement technology of the startup leverages images from ultrasound, computed tomography, and magnetic resonance imaging to analyse vascular imaging. This multimodal technology identifies abnormalities and quantifies changes over time in those at risk. It significantly reduces the time specialists spend on manual image measurements and documentation. As a result, clinicians can dedicate more time to patient care. AIATELLA is currently navigating the medical approval processes in several European and North American countries, including France, the US, and the UK. AIATELLA co-founder and CEO Jack Parker said: 'Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it's too late.' Initially applied to the aorta artery, AIATELLA's vision extends to encompass all blood vessels in the body with its technology. The startup noted that it is also developing a portable ultrasound-based screening technology for mass screening of individuals prior to the occurrence of symptoms. This approach aims to facilitate early detection of cardiovascular diseases, which are a major cause of mortality worldwide. The technology has already been employed in the UK and Finland at screening events, where it has helped identify potentially at-risk individuals. AIATELLA also aims to gather data on the presentation and progression of cardiovascular conditions across different sexes and ethnicities, as symptoms can vary widely among these different groups. "Finland's AIATELLA secures funds for AI cardiovascular imaging solutions" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
